SCHEMBL20333017

SCHEMBL20333017

O=C(O)c1c(O)cccc1CCc1ccc2ccccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOX18 P35713 1/20 1.00
KAT8 Q9H7Z6 3/20 0.58
EP300 Q09472 2/20 0.58
KAT5 Q92993 2/20 0.58
BID P55957 4/20 0.57
MCL1 Q07820 4/20 0.57
BCL2L1 Q07817 3/20 0.57
BAK1 Q16611 3/20 0.57
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50
KAT2A Q92830 1/20 0.50
KAT2B Q92831 1/20 0.50
SAE1 Q9UBE0 1/20 0.50
CYP1A2 P05177 1/20 0.50
PDPK1 O15530 1/20 0.47
PTGER4 P35408 2/20 0.46
PTGER2 P43116 2/20 0.46
TBXA2R P21731 1/20 0.46
PTGFR P43088 1/20 0.46
PTGER3 P43115 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26638944 0.84 SOX18 (0.73) SOX18CYP1A2HDAC1HDAC8
SCHEMBL21530605 0.83 BID (0.79) SOX18KAT8EP300KAT5BID
SCHEMBL20332766 0.82 SOX18 (0.70) SOX18KAT8EP300KAT5CYP1A2
SCHEMBL20332761 0.82 SOX18 (0.70) SOX18KAT8EP300KAT5CYP1A2
SCHEMBL26638875 0.82 SOX18 (0.69) SOX18KAT8EP300KAT5BID
SCHEMBL26744430 0.82 SOX18 (0.69) SOX18KAT8EP300KAT5BID
SCHEMBL574679 0.80 KAT8 (0.69) SOX18KAT8EP300KAT5BID
SCHEMBL20332765 0.80 SOX18 (0.67) SOX18CYP1A2
SCHEMBL26745727 0.78 SOX18 (0.63) SOX18CYP1A2PDPK1PTGER4PTGER2
SCHEMBL20771694 0.73 KAT8 (1.00) SOX18KAT8EP300KAT5BID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355557-A1 ANTIVIRAL SOX INHIBITORS GERTRUDE BIOMEDICAL PTY LTD (AU) 2023-11-09 US disclosed
US-20230355557-A1 ANTIVIRAL SOX INHIBITORS GERTRUDE BIOMEDICAL PTY LTD (AU) 2023-11-09 US disclosed
US-20230355557-A1 ANTIVIRAL SOX INHIBITORS GERTRUDE BIOMEDICAL PTY LTD (AU) 2023-11-09 US disclosed
WO-2022040719-A1 ANTIVIRAL SOX INHIBITORS GERTRUDE BIOMEDICAL PTY LTD (AU) 2022-03-03 WO disclosed
US-20190337880-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES THE UNIVERSITY OF QUEENSLAND (AU) 2019-11-07 US disclosed
WO-2018112545-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS- AND/OR LYMPHANGIOGENESIS-RELATED DISEASES THE UNIVERSITY OF QUEENSLAND (AU) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337880-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES SOX18, PROX1, RUNX1 SOX18 1/4885KAT8 1226/4885EP300 680/4885
US-20230355557-A1 ANTIVIRAL SOX INHIBITORS SOX18, IRF3, YBX1 SOX18 1/4885KAT8 780/4885EP300 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.